Breakthrough in Type 1 Diabetes Treatment at Uppsala University

Advancements in Pancreatic Cell Transplants

Researchers at Uppsala University have reported a significant advancement in the quest to cure type 1 diabetes. Utilizing genetically modified pancreatic cells, the team claims to have discovered a method to prevent a patient’s immune cells from attacking transplanted islet cells, eliminating the need for immunosuppressive drugs. This innovation raises the possibility of routine pancreatic cell transplants for individuals with type 1 diabetes.

Study Findings Published in NEJM

In a study released in the *New England Journal of Medicine* in August 2025, the research team, led by Dr. Per-Ola Carlsson and Dr. Sonja Schrepfer, detailed their approach to addressing the longstanding challenges in developing regenerative treatments for type 1 diabetes. They utilized donated pancreatic cells, reprogramming them to deactivate proteins that attract immune cells.

The researchers surgically implanted these modified cells into a patient with type 1 diabetes and monitored the immune response. Encouragingly, the genetic modifications appeared to protect the cells for a period of twelve weeks until the end of the study.

Progress Towards a Functional Cure

While the study did not permanently cure the patient’s type 1 diabetes, it marked a significant milestone. The researchers demonstrated that their method successfully passed two critical tests: the insulin-producing cells survived the genome editing process and continued to produce insulin, and the genetic modifications effectively camouflaged the cells from the patient’s immune system for at least three months. Future research will focus on determining the optimal number of cells needed for effective insulin production and the longevity of the implanted cells.

Understanding Type 1 Diabetes

The Nature of the Condition

Type 1 diabetes is characterized by the destruction of specialized insulin-producing cells, known as islet cells, within the pancreas. Without these cells, individuals cannot produce insulin, leading to the need for regular insulin injections to manage blood glucose levels. Unlike type 2 diabetes, type 1 diabetes is a lifelong condition that cannot be reversed.

Islet Cells and Their Functions

Islet cells are named for their presence in clusters known as the islets of Langerhans within the pancreas. These clusters contain insulin-producing cells and glucagon-secreting cells. Insulin regulates glucose storage, while glucagon triggers glucose release when energy is needed. Both types of cells are essential for maintaining balanced blood glucose levels.

The Challenges of Pancreas Transplants

Practical Considerations

Despite the potential benefits, several factors complicate the routine application of pancreas transplants for type 1 diabetes. The International Diabetes Federation estimated that in 2025, approximately 9.5 million people worldwide had type 1 diabetes, with around 513,000 new cases each year. Additionally, transplant recipients must take immunosuppressive drugs for life to prevent organ rejection.

While these drugs have improved the quality of life for individuals with immune disorders, they also increase vulnerability to infections and may lead to serious side effects, including cardiovascular and kidney issues, as well as neurological problems. For many, managing diabetes with insulin remains the most practical and affordable option.

The Promise of Stem Cell Therapy

An alternative approach is using a patient’s own stem cells to regenerate missing insulin-producing islet cells. This method, which aims to avoid transplant rejection and immunosuppression, is a key focus of regenerative medicine research. However, type 1 diabetes poses unique challenges due to its autoimmune nature, where the immune system mistakenly targets islet cells.

Understanding the Autoimmune Response

Genetic Factors at Play

More than 90% of individuals diagnosed with type 1 diabetes possess genetic mutations affecting components of the immune system. Specifically, the HLA-DR3 and HLA-DR4 proteins, part of the Human Leukocyte Antigen system, play a crucial role in the immune response. These proteins help alert the immune system to pathogens, but in type 1 diabetes, they may mistakenly identify islet cells as threats.

The Immune System’s Response

This misidentification leads the immune system to target and destroy the islet cells, complicating efforts to regenerate new cells. Without immunosuppression, using pancreatic stem cells or transplanting islet cells from donors poses significant challenges.

Innovative Solutions from Uppsala University

Gene Editing Techniques

To circumvent the immune response issue, Carlsson and his team employed a novel strategy. They hypothesized that if the donated cells could not form the antigen display complex, they would evade detection by the immune system. By removing the HLA genes that attract immune cells and adding a gene to repel those cells, they aimed to ensure the survival of the transplanted islet cells.

A 42-year-old man with a long history of type 1 diabetes volunteered for this innovative trial. The researchers carefully selected a donor to minimize immune response and then edited the islet cells’ genomes to remove the HLA genes before implanting them into the patient.

Monitoring the Results

Following the implantation of 79.6 million genetically engineered islet cells, the team monitored the patient’s immune response over a 12-week period. They found that cells with both HLA classes triggered an immune response, while those lacking HLA genes survived longer, particularly when carrying the additional CD47 gene.

Results and Future Directions

Insulin Production and Patient Monitoring

By the end of the twelve-week observational period, the implanted cells exhibited promising insulin production, as indicated by rising C peptide levels after meals. The patient continued to use his regular insulin regimen, but the implanted cells contributed to his insulin production.

Looking Ahead

The researchers are committed to further investigating the longevity of these implanted cells and their ongoing insulin production capabilities. This study represents a significant step toward enabling pancreatic cell transplants without the need for immunosuppression.

Conclusion: A New Era for Diabetes Treatment

The findings from Uppsala University highlight the potential for pancreatic cell transplants in treating type 1 diabetes without immunosuppressive drugs. This marks a pivotal moment in diabetes research, with the possibility of human pancreatic cell implants finally within reach. The deletion of HLA proteins in donor pancreas cells could pave the way for successful transplants that were previously deemed too complex. As research continues, the future of islet cell transplants looks promising.

Reference

Carlsson PO, Hu X, Scholz H, et al. Survival of Transplanted Allogeneic Beta Cells with No Immunosuppression. *New England Journal of Medicine*. 0(0). doi:10.1056/NEJMoa2503822